• Capricor Therapeutics reported The Lancet published results from its Phase 3 HOPE-3 trial of deramiocel in Duchenne muscular dystrophy.
• Results were already presented in the journal publication, not flagged for a future conference readout.
• The study met its main goal, showing deramiocel slowed functional decline versus placebo in largely non-ambulatory patients.
• Data also indicated a clinically meaningful benefit in heart function, supporting a broader disease-modifying effect.
• Deramiocel’s BLA remains under FDA review, with a PDUFA target action date of Aug. 22, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607291005PRIMZONEFULLFEED9800202) on July 29, 2026, and is solely responsible for the information contained therein.